Abstract
The aim of this study was to compare the effect of different long-term chelation regimens on heart and liver iron stores with the use of T2* magnetic resonance imaging (MRI) in patients with transfusion-dependent β-thalassemia major. Sixty-four patients (28 men, 36 women; mean age, 26.49 ± 5.8 years) were enrolled in the study. The 3 groups were based on the chelation therapy received. The first group (19 patients) received deferiprone (DFP) (75 mg/kg per day orally), the second group (23 patients) received deferoxamine (DFO) (30–50 mg/kg per day subcutaneously at least 5 times/week), and the third group (22 patients) received a combination of DFO (30–50 mg/kg per day, 2–3 days/week) and DFP (75 mg/kg per day, 7 days/week). MRI scans were acquired with an imager equipped with a 1.5 T magnet, and the data included myocardial and hepatic iron measurements obtained by means of T2*, and ventricular volumes and ejection fractions obtained with standard cardiovascular MRI techniques. The results revealed that the DFP and the combined groups had significantly less myocardial iron than the DFO group (mean myocardial T2*, 35.77 ± 18.3 milliseconds and 38.05 ± 15.3 milliseconds versus 23.77 ± 13 milliseconds [P =.02, andP =.001], respectively). On the contrary, the DFP group had a significantly higher hepatic iron content than the DFO and combined groups (mean hepatic T2*, 3.29 ± 2.5 milliseconds versus 8.16 ± 8.4 milliseconds and 11.3 ±10.9 milliseconds [P =.014, andP =.003], respectively). No correlation was observed between myocardial T2* and hepatic T2* values (r =-0.043;P =.37). Myocardial T2* values were inversely correlated with age (r =-0.249;P =.024) and positively correlated with both left and right ventricular ejection fractions (r = 0.33 [P =.004], andr = 0.279 [P =.014], respectively). Finally, liver T2* was strongly and inversely correlated with serum ferritin concentration (r =-0.465;P =.001). In conclusion, combined chelation therapy seems to sum the beneficial effects of DFO and DFP with respect to hepatic and myocardial iron. Because myocardial iron is not related to measurements of serum ferritin or hepatic T2*, important decisions on clinical management relating to cardiac risk should not rely on these conventional parameters. Thus, the use of MRI for assessing myocardial iron should be adopted in the routine clinical management of patients with β-thalassemia major.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia.Ann N Y Acad Sci. 2005;1054:40–47.
Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, and the Thalassemia Clinical Research Network. Complications of β-thalassemia major in North America.Blood. 2004;104:34–39.
Piga A, Gaglioti C, Fogliacco E,Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.Haematologica. 2003;88:489–496.
Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.Blood. 2005;106:3242–3250.
Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.J Lab Clin Med. 2001;138:130–138.
Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine.Br J Haematol. 1998;103:361–364.
Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.Br J Haematol. 2003;121:187–189.
Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major.Haematologica. 2005;90:1309–1314.
Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.Ann Hematol. 2006;85:315–319.
Johnston DL, Rice L, Vick GW 3rd, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging.Am J Med. 1989;87:40–47.
Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop.Blood. 2003;101:15–19.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.Eur Heart J. 2001;22:2171–2179.
Bellenger NG, Francis JM, Davies CL, Coats AJ, Pennell DJ. Establishment and performance of a magnetic resonance cardiac function clinic.J Cardiovasc Magn Reson. 2000;2:15–22.
Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging.J Cardiovasc Magn Reson. 1999;1:7–21.
Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. atThalassemia.HematologyAm Soc Hematol Educ. Program 2004:14–34.
Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients.Blood. 2005;106:1460–1465.
Jensen PD. Evaluation of iron overload.Br J Haematol. 2004;124:697–711.
Gossuin Y, Roch A, Muller RN, Gillis P. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange.Magn Reson Med. 2000;43:237–243.
Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques.Radiology. 1999;212:227–234.
Perifanis V, Economou M, Christoforides A, Koussi A,Tsitourides I, Athanassiou-Metaxa M. Evaluation of iron overload in beta-thalassemia patients using magnetic resonance imaging.Hemoglobin. 2004;28:45–49.
Christoforidis A, Haritandi A, Tsitouridis I, et al. Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients.J Pediatr Hematol Oncol. 2006;28:311–315.
Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia.J Magn Reson Imaging. 2003;18:616–620.
Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, on behalf of the Thalassemia International Federation Heart T2* Investigators. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron.Haematologica. 2006;91:1388–1391.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia.Lancet. 2002;360:516–520.
Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in β-thalassemia major by multislice multiecho T2*.Eur J Haematol. 2006;76:183–192.
Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan.Eur J Haematol. 2003;70:392–397.
Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.Blood. 1995;86:2008–2013.
de Franceschi L, Shalev O, Piga A, et al. Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity.J Lab Clin Med. 1999;133:64–69.
Porter JB.Development of Primary Hepatocyte Cultures for the Preclinical Evaluation of Iron Chelators [MD thesis]. Cambridge, UK: University of Cambridge; 1999.
Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassaemia major: comparison between different chelation regimens.Eur J Haematol. 2007;78:52–57.
Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.Blood Cells Mol Dis. 2006;36:21–25.
Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia: the protocol of the International Committee on Oral Chelators.Hemoglobin. 2006;30:239–249.
Tanner MA, Galanello R, Dessi C, et al. The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endothelial function in thalassemia major: a randomized controlled trial using cardiovascular magnetic resonance [abstract].Haematologica. 2006;91(suppl 1). Abstract 0517.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Perifanis, V., Christoforidis, A., Vlachaki, E. et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major. Int J Hematol 86, 385–389 (2007). https://doi.org/10.1007/BF02983992
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983992